Compare EBMT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBMT | AGEN |
|---|---|---|
| Founded | 1922 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.7M | 147.4M |
| IPO Year | 2009 | 1999 |
| Metric | EBMT | AGEN |
|---|---|---|
| Price | $23.25 | $3.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.00 | $14.50 |
| AVG Volume (30 Days) | 50.3K | ★ 557.3K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | 53.23 | ★ 100.00 |
| EPS | 0.51 | ★ 1.02 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $45.90 | ★ $3.01 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $15.11 | $2.71 |
| 52 Week High | $23.95 | $7.34 |
| Indicator | EBMT | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 68.76 | 49.01 |
| Support Level | $21.59 | $2.93 |
| Resistance Level | $23.69 | $3.38 |
| Average True Range (ATR) | 0.56 | 0.22 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 88.84 | 66.33 |
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.